CIK 0002070849 · Non-accelerated filer<br>Emerging growth company
BillionToOne, Inc.
Sign in to watch- Ticker
- BLLN
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811082020
- Phone
- 650-460-2551
- Business address
- 1035 O'BRIEN DRIVE, MENLO PARK, CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $26,737,121
- in 19 filings, $26.7M under 10b5-1 plans
Net −$26,737,121. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-02 | Tsao David Chief Technology Officer | Sale 10b5-1 | −1,992 | $110.13 | $219K | 12,530 |
| 2026-11-02 | Tsao David Chief Technology Officer | Sale 10b5-1 | −1,130 | $110.77 | $125K | 11,400 |
| 2026-11-02 | Tsao David Chief Technology Officer | Sale 10b5-1 | −300 | $112.19 | $34K | 11,100 |
| 2026-11-02 | Tsao David Chief Technology Officer | Sale 10b5-1 | −100 | $113.17 | $11K | 11,000 |
| 2026-11-02 | Tsao David Chief Technology Officer | Sale 10b5-1 | −1,063 | $107.33 | $114K | 9,937 |
| 2026-11-02 | Tsao David Chief Technology Officer | Sale 10b5-1 | −2,450 | $108.39 | $266K | 7,487 |
| 2026-11-02 | Tsao David Chief Technology Officer | Sale 10b5-1 | −3,234 | $109.15 | $353K | 4,253 |
| 2026-11-02 | Tsao David Chief Technology Officer | Sale 10b5-1 | −2,389 | $110.31 | $264K | 1,864 |
| 2026-11-02 | Tsao David Chief Technology Officer | Sale 10b5-1 | −633 | $111.14 | $70K | 1,231 |
| 2026-11-02 | Tsao David Chief Technology Officer | Sale 10b5-1 | −208 | $112.01 | $23K | 1,023 |
| 2026-11-02 | Tsao David Chief Technology Officer | Sale 10b5-1 | −23 | $113.17 | $3K | 1,000 |
| 2026-11-02 | Tsao David Chief Technology Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −10,000 | $2.80 | $28K | 526,667 |
| 2026-11-02 | Tsao David Chief Technology Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −10,000 | $2.80 | $28K | 516,667 |
| 2026-11-02 | ten Bosch John Roderick SVP of Laboratory Operations | Sale 10b5-1 | −1,417 | $113.17 | $160K | 17,968 |
| 2026-11-02 | ten Bosch John Roderick SVP of Laboratory Operations | Sale 10b5-1 | −1,417 | $113.17 | $160K | 16,551 |
| 2026-10-28 | Atay Oguzhan Chairman and CEO | Option exercise 10b5-1 | +8,333 | $2.80 | $23K | 8,333 |
| 2026-10-28 | Atay Oguzhan Chairman and CEO | Sale 10b5-1 | −8,333 | $118.00 | $983K | 0 |
| 2026-10-28 | Atay Oguzhan Chairman and CEO | Sale 10b5-1 | −2,667 | $118.00 | $315K | 146,501 |
| 2026-10-28 | Atay Oguzhan Chairman and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −8,333 | $2.80 | $23K | 460,296 |
| 2026-10-15 | Atay Oguzhan Chairman and CEO | Option exercise 10b5-1 | +5,150 | $2.80 | $14K | 5,150 |
Page 3 of 32 · 639 trades